Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Wolfspeed Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Wolfspeed Inc trades at $23.57 (market cap $1.51B). The key difference: Wolfspeed Inc is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Wolfspeed Inc for 20 Days on average.
| MRVI | WOLF | |
|---|---|---|
Market Cap | $972.90M | $1.51B |
Volume | 4,325,710 | 3,682,639 |
Sector | Health | Technology |
52-Week High | $9.00 | $73.68 |
52-Week Low | $2.83 | $14.80 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $1.08B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Wolfspeed (WOLF) trades at $28.67, up 2.25% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The company shows severe financial strain with negative gross margins of -16.05% and net losses of -$1.61B in 2025, though 2026 projects a return to profitability. Recent news highlights expansion of 200mm silicon carbide technology and ongoing investor litigation investigations.
The stock presents high-risk speculative potential with analyst consensus target of $54.32 suggesting significant upside, but requires successful execution on revenue growth and margin improvement. Key risks include persistent negative profitability, high debt burden, and competitive pressures in the semiconductor materials sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
